Regular Article
Condyloma Eradication: Self-Therapy with 0.15–0.5% Podophyllotoxin versus 20–25% Podophyllin Preparations—An Integrated Safety Assessment

https://doi.org/10.1006/rtph.2000.1446Get rights and content

Abstract

Topical application of podophyllin solution, long considered the therapy of first choice against condylomata acuminata, can no longer be recommended due to its low efficacy and gross toxicity. Self-treatment with 0.15–0.5% purified podophyllotoxin preparations, applied twice daily for 3 days, is now advocated as the alternative first-line therapy of choice, when significant improvement is conveniently, and cost-effectively, accomplished within a few weeks. This review provides a summary of the comparative efficacy and utility of podophyllin versus podophyllotoxin as well as a compilation of in vivo and in vitro safety evaluations. In light of overwhelming safety and efficacy data in favor of podophyllotoxin-derived products, it is concluded that podophyllin preparations have no place in the modern treatment portfolio for anogenital warts.

References (152)

  • L. Koutsky et al.

    Genital papillomavirus infections: Current knowledge and future prospects

    Obstet. Gynecol. Clin. North Am.

    (1989)
  • A. Langenberg et al.

    Dual infection with human papillomavirus in a population with overt genital condylomas

    J. Am. Acad. Dermatol.

    (1993)
  • A. Lassus

    Comparison of podophyllotoxin and podophyllin in treatment of genital warts

    Lancet

    (1987)
  • M. Melbye et al.

    The role of human papillomaviruses in anogenital cancers

    Semin. Cancer Biol.

    (1998)
  • J.H. Scholefield et al.

    Anal intraepithelial neoplasia: Part of a multifocal disease process

    Lancet

    (1992)
  • J. Aznar et al.

    Dual genitotropic human papillomavirus infections in genital warts

    Genitourin. Med.

    (1993)
  • S.A. Bashi

    Cryotherapy versus podophyllin in the treatment of genital warts

    Int. J. Dermatol.

    (1985)
  • H.M. Bauer et al.

    Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon

    Sex. Transm. Dis.

    (1993)
  • I. Berenblum

    The effect of podophyllotoxin on the skin of the mouse with reference to carcinogenic, co-carcinogenic and anti-carcinogenic action

    J. Natl. Cancer Inst.

    (1951)
  • K.R. Beutner et al.

    Current status of podophyllotoxin for the treatment of genital warts

    Semin. Dermatol.

    (1990)
  • L.F. Bjeldanes et al.

    Mutagenic activity of quercetin and related compounds

    Science

    (1977)
  • C.F. Brewer et al.

    Conformational analysis of podophyllotoxin and its congeners: Structure–activity relationship in microtubule assembly

    J. Med. Chem.

    (1979)
  • C. Brigati et al.

    CPH-86: A highly purified podophyllotoxin efficiently suppresses in vivo and in vitro immune responses

    J. Immunopharmacol.

    (1985)
  • W. Busse

    The significance of quality for efficacy and safety of herbal medicinal products

    Drug Inform. J.

    (2000)
  • D.E. Cassidy et al.

    Podophyllum toxicity: A review of a fatal case and a review of the literature

    J. Toxicol.-Clin. Toxicol.

    (1982)
  • X. Castellsagu et al.

    Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: A study in Spain and Columbia

    JID

    (1997)
  • Centers for Disease Control and Prevention (CDC) 1998. 1998 guidelines for treatment of sexually transmitted diseases....
  • M.J. Chamberlain et al.

    Toxic effect of podophyllum application in pregnancy

    Br. Med. J.

    (1972)
  • U. Claesson et al.

    Topical treatment of venereal warts: A comparative open study of podophyllotoxin cream versus solution

    Int. J. STD AIDS

    (1996)
  • Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal...
  • P.F. Conard et al.

    Delayed recognition of podophyllin toxicity in a patient receiving epidural morphine

    Anaesthiol. Analg.

    (1990)
  • Podophyllin and Podophyllotoxin: Reverse Mutation in Five Histidine-Requiring Strains of Salmonella typhimurium.

    (June 1997)
  • F.M. Cowen

    Evidence-based medicine: An overview

    Int. J. STD AIDS

    (1999)
  • Podophyllotoxin CPH-86: L5178Y TK+/− Mouse Lymphoma Mutation Assay.

    (July 2000)
  • Podophyllotoxin CPH-86: Mouse Bone Marrow Micronucleus Test.

    (July 2000)
  • A.L. Cubilla et al.

    Squamous cell carcinoma of the penis; premalignant lesions

    Urology (Suppl.)

    (2000)
  • H.W. Detrich et al.

    Effect of colchicine binding on the reversible dissociation of the tubulin dimer

    Biochemistry

    (1982)
  • K.A. Didcock et al.

    The action of some nucleotoxic substances on pregnancy

    Br. J. Pharmacol.

    (1956)
  • G.J. Dobb et al.

    Coma and neuropathy after ingestion of herbal laxative containing podophyllin

    Med. J. Aust.

    (1984)
  • J.J. Dwornick

    The Effect of Podophyllin and Temperature on Skeletal Development of the Holtzman Albino Rat

    (1969)
  • A. Edwards et al.

    Podophyllotoxin 0.5% podophyllin 20% to treat penile warts

    Genitourin. Med.

    (1988)
  • Ferenczy, A., and von Krogh, G.2000. External genital warts: Current and new therapies. In Management of Anogenital...
  • C.M. Filley et al.

    Neurological manifestations of podophyllin toxicity

    Neurology

    (1982)
  • A.A. Fisher

    Severe systemic and local reactions to topical podophyllin resin

    Cutis

    (1981)
  • P.A. Fraser et al.

    Motion; Podophyllotoxin is superior to podophyllin in the treatment of genital warts

    J. Eur. Acad. Dermatol. Venereol.

    (1993)
  • J.A. Gray et al.

    Commentary on the Mutagenic Potential of Podophyllin and Podophyllotoxin.

    (1996)
  • M.D. Greenberg et al.

    A double blind randomised trial of 0.5% podophilox and placebo for the treatment of genital warts in women

    Obstet. Gynecol

    (1991)
  • L.A. Habel et al.

    Risk factors for incident and recurrent condylomata acuminata among women

    Sex. Transm. Dis.

    (1998)
  • A. Heath et al.

    Treatment of podophyllin poisoning with resin hemoperfusion

    Hum. Toxicol.

    (1982)
  • C.S. Herrington

    Do HPV-negative cervical carcinomas exist?—Revisited

    J. Pathol.

    (1999)
  • Cited by (49)

    • Bioprospecting and bioassay-guided isolation of medicinal plants—A tool for drug discovery

      2022, Evidence-Based Validation of Herbal Medicine: Translational Research on Botanicals
    • Cryptic solvation dynamics of potential antineoplastic Azapodophyllotoxin: Short and long range charge transfer and distinct H-bonding motifs demystify its swinging emissive behaviour

      2022, Journal of Photochemistry and Photobiology A: Chemistry
      Citation Excerpt :

      Presently, its most widely accepted semisynthetic derivatives, etoposide [9], etopophos [10] and teniposide [11] are working as anticancer drugs as DNA topoisomerase II inhibitors unlike PPT which acts as inhibitor of tubulin polymerization. However, in spite of such diverse abilities, the PPT and its derivatives are shelved on account of its intractable toxicities and severe adverse effects [12] and hence many attempts have been made to improve the cyclolignan skeleton aiming to keep the properties intact. Bearing this in mind, an emerging class of azapodophyllotoxin (AZP) [13–18] fluorophores have been introduced as nitrogen analogues of parent PPT thereby adding a new dimension in this area of clinical research.

    • Novel podophyllotoxin and benzothiazole derivative induces transitional morphological and functional changes in HaCaT cells

      2021, Toxicology in Vitro
      Citation Excerpt :

      Molecules of natural origin and their derivatives serve as scaffolds for the invention and synthesis of novel drugs. Podophyllotoxin (PPT) is the main constituent of roots and rhizomes of the plants from the genus Podophyllum belonging to Berberidaceae family (Lewis and Goldmeier, 1995; Longstaff and von Krogh, 2001; von Krogh and Longstaff, 2001). The exact mechanism of PPT action in human cells is not fully known.

    • Role of aneuploidy in the carcinogenic process: Part 3 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases

      2019, Mutation Research - Genetic Toxicology and Environmental Mutagenesis
      Citation Excerpt :

      Podophyllotoxin has been shown to induce aneuploidy in hamster oocytes [248]. No oncogenic effects were seen in two 80-week mouse carcinogenicity tests dosed at up to 3.0 mg/kg/day (dermal and dietary) and in a 2-year rat dietary study at doses up to 0.3 mg/kg/day [250]. There were no data presented on plasma exposure levels in these studies.

    • Human papillomavirus-related genital disease in the immunocompromised host: Part II

      2012, Journal of the American Academy of Dermatology
      Citation Excerpt :

      Unpurified podophyllum was previously used as a provider-applied treatment for anogenital warts, however, because of its low efficacy, high toxicity, and a serious mutagenicity profile, it should no longer be included in recommended clinical treatment protocols, and should be entirely replaced by patient-applied, purified podophyllotoxin (level IIB evidence).32 Podophyllotoxin is preferred over podophyllum not only for its purity, stability, and lack of systemic toxicity, it has also been shown to have greater efficacy and cost effectiveness than clinic-based treatment with podophyllin (level IIB evidence),33 with the added convenience of home therapy.32-38 In a large randomized controlled trial, Lacey et al33 found that podophyllotoxin solution and cream were three and two and a half times more likely, respectively, to produce cure than podophyllin.

    View all citing articles on Scopus

    Reprint requests should be addressed to Mrs. Sue Mayne at Stiefel Laboratories R & D, Holtspur Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0AU, United Kingdom.

    View full text